Division of Infectious Diseases, The Hospital for Sick Children, Toronto, Canada.
Paediatric Emergency Department, Hospices Civils de Lyon, Hôpital Femme Mère Enfant, Lyon, France.
PLoS One. 2022 Aug 24;17(8):e0272648. doi: 10.1371/journal.pone.0272648. eCollection 2022.
There are limited data on outcomes of SARS-CoV-2 infection among infants (<1 year of age). In the absence of approved vaccines for infants, understanding characteristics associated with hospitalization and severe disease from COVID-19 in this age group will help inform clinical management and public health interventions. The objective of this study was to describe the clinical manifestations, disease severity, and characteristics associated with hospitalization among infants infected with the initial strains of SARS-CoV-2.
This is a national, prospective study of infants with SARS-CoV-2 from April 8th 2020 to May 31st 2021 using the infrastructure of the Canadian Paediatric Surveillance Program. Infants <1 year of age with microbiologically confirmed SARS-CoV-2 infection from both inpatients and outpatients seen in clinics and emergency departments were included. Cases were classified as either: 1) Non-hospitalized patient with SARS-CoV-2 infection; 2) COVID-19-related hospitalization; or 3) non-COVID-19-related hospitalization (e.g., incidentally detected SARS-CoV-2). Case severity was defined as asymptomatic, outpatient care, mild (inpatient care), moderate or severe disease. Multivariable logistic regression was performed to identify characteristics associated with hospitalization.
A total of 531 cases were reported, including 332 (62.5%) non-hospitalized and 199 (37.5%) hospitalized infants. Among hospitalized infants, 141 of 199 infants (70.9%) were admitted because of COVID-19-related illness, and 58 (29.1%) were admitted for reasons other than acute COVID-19. Amongst all cases with SARS-CoV-2 infection, the most common presenting symptoms included fever (66.5%), coryza (47.1%), cough (37.3%) and decreased oral intake (25.0%). In our main analysis, infants with a comorbid condition had higher odds of hospitalization compared to infants with no comorbid conditions (aOR = 4.53, 2.06-9.97), and infants <1 month had higher odds of hospitalization then infants aged 1-3 months (aOR = 3.78, 1.97-7.26). In total, 20 infants (3.8%) met criteria for severe disease.
We describe one of the largest cohorts of infants with SARS-CoV-2 infection. Overall, severe COVID-19 in this age group was found to be uncommon. Comorbid conditions and younger age were associated with COVID-19-related hospitalization amongst infants.
目前关于 SARS-CoV-2 感染在婴儿(<1 岁)中的结局数据有限。由于婴儿尚未批准疫苗,了解该年龄段内 COVID-19 相关住院和重症的特征有助于为临床管理和公共卫生干预措施提供信息。本研究的目的是描述感染 SARS-CoV-2 的初始毒株的婴儿的临床表现、疾病严重程度以及与住院相关的特征。
这是一项全国性、前瞻性研究,利用加拿大儿科监测计划的基础设施,对 2020 年 4 月 8 日至 2021 年 5 月 31 日期间患有 SARS-CoV-2 的婴儿进行研究。包括门诊和急诊科就诊的 1 岁以下、经微生物学证实患有 SARS-CoV-2 感染的住院和门诊患儿。病例分为:1)非住院 SARS-CoV-2 感染患者;2)COVID-19 相关住院;或 3)非 COVID-19 相关住院(例如,偶然发现的 SARS-CoV-2)。病例严重程度定义为无症状、门诊治疗、轻症(住院治疗)、中症或重症。采用多变量逻辑回归分析确定与住院相关的特征。
共报告了 531 例病例,包括 332 例(62.5%)非住院和 199 例(37.5%)住院婴儿。在住院婴儿中,199 例中有 141 例(70.9%)因 COVID-19 相关疾病住院,58 例(29.1%)因急性 COVID-19 以外的其他原因住院。在所有 SARS-CoV-2 感染病例中,最常见的首发症状包括发热(66.5%)、流涕(47.1%)、咳嗽(37.3%)和摄入减少(25.0%)。在我们的主要分析中,患有合并症的婴儿与无合并症的婴儿相比,住院的可能性更高(aOR=4.53,2.06-9.97),<1 个月的婴儿与 1-3 个月的婴儿相比,住院的可能性更高(aOR=3.78,1.97-7.26)。共有 20 例(3.8%)患儿符合重症疾病标准。
我们描述了其中一个最大的 SARS-CoV-2 感染婴儿队列。总体而言,该年龄段严重 COVID-19 并不常见。合并症和年龄较小与婴儿 COVID-19 相关住院相关。